The High-Throughput Screening Core allows the rapid identification of biologically active chemicalscaffolds from libraries containing several thousand discrete chemicals, and potentially containing naturallyoccurring ones obtained from natural sources such as plants. MSKCC has implemented the creation of astate of the art high throughput screening core facility with modern robotics, custom built screening datamanagement databases for storing and querying data, and setting up strategic collaborations for the supplychemicals and to provide expertise in medicinal chemistry optimization. The facility contains a custom builtsix meter linear track robotic platform equipped with plate hotels, incubators for cell based assays, bulk liquiddispensers (Multidrops), 384/1536 liquid handlers (Apricot Designs TPS), a Perkin Elmer MicroBeta counter,two Perkin Elmer Victors multi-detection plates readers, two Molecular Device absorbance scanners, andone Amersham Multi-detection imager. Screening data acquisition and management is handled throughcustom built software named ORIS, which is composed of a chemical registration and inventory functiontogether with an automated data loader for acquisition, analysis and screen data publishing. The compoundlibrary will grow to up to 500,000 discrete chemicals from selected commercial vendors and will also containa wide variety of natural products, some purified and others in extract mixtures pending screening and dereplicationto identify and purify the active product(s). The impact of such an infrastructure on the ongoingcancer research will be in the following areas: 1) Chemical cancer biology to discover novel controlmechanisms to help further elucidate known or discover novel cancer pathways including control junctions,2) Novel chemical scaffolds for use as radiotracers for biochemical and metabolic studies in vivo and for usein cancer diagnostics, and 3) the classical drug discovery process in which in vitro and/or cell based targetsare screened and the resulting chemical hits are subjected to secondary and high content screens, in orderto further optimize their chemical structures and their drug properties, and to show some efficacy against thespecific cancer with little or no side effects, making them good drug candidates for the clinic.
Showing the most recent 10 out of 8799 publications
